Pilot Study to Assess the Efficacy and Tolerance to a QUadruple Therapy With Asunaprevir , Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a, in HIV-HCV Genotype 1 or 4 Coinfected Patients Previously Null Responders to a Standard Pegylated Interferon -Ribavirin Regimen
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms QUADRIH
- 05 Oct 2015 Results published in the Antimicrobial Agents and Chemotherapy.
- 25 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Aug 2013 Planned End Date changed from 1 Oct 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.